|
|
|
Insider
Information: |
Baker Brothers Life Sciences Lp |
Relationship: |
Director |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
15 |
|
Direct
Shares |
28,278,373 |
|
Indirect Shares
|
99,473,529 |
|
|
Direct
Value |
$941,991,056 |
|
|
Indirect Value
|
$2,801,738,789 |
|
|
Total
Shares |
127,751,902 |
|
|
Total
Value |
$3,743,729,845 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
13
|
1
|
Stock
price went up :
|
11
|
0
|
Stock
price went down : |
2
|
1
|
|
|
|
Gain/Loss Ratio : |
5.5
|
-1.0
|
Percentage
Gain/Loss : |
19.7%
|
-23.5%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Synageva BioPharma Corp |
GEVA |
Director |
2012-07-13 |
5,077,676 |
|
0 |
Premium* |
|
XOMA Corporation |
XOMA |
Director |
2012-07-19 |
13,606,093 |
|
0 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director |
2012-07-26 |
9,086,690 |
|
0 |
Premium* |
|
Acadia Pharmaceuticals Inc |
ACAD |
Director, 10% Owner |
2023-06-01 |
205,752 |
2023-06-01 |
39,330,977 |
Premium* |
|
Seagen Inc |
SGEN |
Former 10% Owner, Dire... |
2023-12-14 |
0 |
2023-12-14 |
0 |
Premium* |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2017-09-08 |
119,681 |
2017-09-08 |
822,826 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2014-03-10 |
1,613,076 |
Premium* |
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2017-06-15 |
131,963 |
2017-06-15 |
1,074,556 |
Premium* |
|
Beigene Ltd |
BGNE |
Director, 10% Owner |
2023-11-14 |
20,838 |
2023-11-14 |
9,878,124 |
Premium* |
|
Talis Biomedical Corp |
TLIS |
Director, 10% Owner |
2021-11-18 |
0 |
2021-11-18 |
7,625,425 |
Premium* |
|
Tscan Therapeutics, Inc. |
TCRX |
Director, 10% Owner |
2022-05-10 |
0 |
2022-05-11 |
2,528,583 |
Premium* |
|
DBV Technologies SA |
DBVT |
Director, 10% Owner |
2022-06-13 |
0 |
2022-06-13 |
29,190,248 |
Premium* |
|
Kiniksa Pharmaceuticals, Ltd. |
KNSA |
Director |
2023-06-06 |
29,680 |
2023-06-06 |
2,719,343 |
Premium* |
|
Igm Biosciences, Inc. |
IGMS |
Director |
2023-06-30 |
0 |
2023-09-29 |
2,896,968 |
Premium* |
|
Madrigal Pharmaceuticals Inc |
MDGL |
Director |
2023-11-14 |
0 |
2023-12-14 |
1,793,403 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
114 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
GEVA |
Synageva BioPharma Corp |
Director |
|
2012-07-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,077,676 |
|
- |
|
XOMA |
XOMA Corporation |
Director |
|
2012-07-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,606,093 |
|
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2012-07-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,086,690 |
|
- |
|
ACAD |
Acadia Pharmaceuticals In... |
Director |
|
2013-01-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,229,612 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2013-05-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,131,223 |
|
- |
|
INCY |
Incyte Corp |
Director |
|
2013-06-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,000 |
|
- |
|
INCY |
Incyte Corp |
Director |
|
2013-06-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,430,783 |
|
- |
|
ACGN |
Aceragen, Inc |
Director |
|
2014-03-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,613,076 |
|
- |
|
INCY |
Incyte Corp |
Director |
|
2017-03-31 |
4 |
A |
$133.67 |
$56,943 |
I/I |
426 |
767,237 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2016-12-30 |
4 |
A |
$100.27 |
$56,853 |
I/I |
567 |
533,909 |
0 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2023-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,108 |
2,896,414 |
0 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2023-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,108 |
2,896,968 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Director |
|
2017-05-10 |
4 |
A |
$0.00 |
$0 |
I/I |
4,060 |
6,106,592 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Director |
|
2017-06-14 |
4 |
B |
$118.00 |
$518,256 |
I/I |
4,392 |
7,321,850 |
2.1 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2015-05-15 |
4 |
A |
$39.94 |
$295,556 |
I/I |
7,400 |
26,054,500 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2016-05-20 |
4 |
A |
$38.82 |
$287,268 |
I/I |
7,400 |
38,787,087 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2017-05-19 |
4 |
A |
$66.60 |
$492,840 |
I/I |
7,400 |
40,898,792 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2015-03-10 |
4 |
B |
$34.47 |
$321,921 |
I/I |
9,319 |
25,008,136 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2015-11-10 |
4 |
B |
$44.00 |
$413,600 |
I/I |
9,400 |
33,099,494 |
2.25 |
- |
|
BGNE |
Beigene Ltd |
Director |
|
2017-10-13 |
4 |
A |
$0.00 |
$0 |
D/D |
14,204 |
7,102 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2015-11-18 |
4 |
B |
$43.00 |
$638,321 |
I/I |
14,638 |
33,114,132 |
2.25 |
- |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-11-15 |
4 |
B |
$161.97 |
$2,461,721 |
I/I |
15,199 |
1,545,775 |
2.1 |
% |
|
KNSA |
Kiniksa Pharmaceuticals, ... |
Director |
|
2023-06-06 |
4 |
A |
$0.00 |
$0 |
I/I |
17,492 |
2,719,343 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2015-05-11 |
4 |
OE |
$5.11 |
$102,200 |
I/I |
20,000 |
26,050,800 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2016-03-08 |
4 |
OE |
$4.18 |
$83,600 |
I/I |
20,000 |
36,692,540 |
0 |
- |
|
114 Records found
|
|
Page 1 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|